Genmab A/S, an international biotechnology company, has appointed Margarida Duarte as General Manager, Europe and Emerging Markets, as the company continues to scale its commercialization presence to bring its antibody-based medicines to more patients with cancer.

As part of its continued expansion, Genmab has appointed Duarte to lead its commercial business in Europe and Emerging Markets. In this role, she will oversee business operations across these commercial markets, with responsibility for driving alignment, performance and launch excellence to advance the company’s mission to improve the lives of patients with cancer and other serious diseases.

“We are very pleased to welcome Margarida to Genmab at an important stage in our growth,” said Brad Bailey, Executive Vice President and Chief Commercial Officer of Genmab. “Margarida’s proven ability to build and scale high-performing organizations, deliver successful oncology launches across complex markets, and lead through transformation make her exceptionally well suited to accelerate our momentum in Europe and expand our impact for patients.”

Experience

Duarte joins Genmab with more than 20 years of international leadership experience in the biotech sector with a specialized focus in oncology. Most recently, she served as Executive Vice President and Chief Commercial Officer at Deciphera Pharmaceuticals, where she was responsible for commercialization across U.S., Europe and distributor markets. She led the company’s transition to a multiproduct organization.

Earlier in her career, Duarte held senior leadership roles at Alnylam Pharmaceuticals, Exelixis, Onyx Pharmaceuticals and Amgen, where she led European commercialization strategies, built high-performing teams and oversaw major oncology launches across diverse healthcare systems.

“I am proud to join Genmab, a company recognized for its pioneering antibody science and strong commitment to patients,” said Duarte. “I look forward to partnering with colleagues across our markets and engaging with external stakeholders to help broaden the impact of our innovative antibody-based medicines for patients.”